Human luteinizing hormone superagonists
View Patent ↗The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the β-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone. The invention is also directed to a method of constructing superactive nonchimeric analogs of human hormones comprising comparing the amino acid sequence of a more active homolog from another species to the human hormone, and selecting superactive analogs from the substituted human hormones. The invention is also directed to nucleic acids encoding the modified human glycoprotein hormones, vectors containing those nucleic acids, and host cells containing those vectors.
1. A modified human luteinizing hormone (LH) comprising an α subunit and a β subunit, said α subunit comprising at least three basic amino acids at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20.
2. The modified LH of claim 1 , wherein said α subunit further comprises a fourth basic amino acid at a position selected from the group consisting of positions 11, 13, 14, 16, 17, and 20.
3. The modified LH of claim 2 , wherein said basic amino acids in the α subunit are at positions 11, 13, 16, and 20.
4. The modified LH of claim 2 , wherein said basic amino acids in the α subunit are at positions 11, 13, 17, and 20.
5. The modified LH of claim 2 , wherein said basic amino acids in the α subunit are at positions 13, 14, 16, and 20.
6. The modified LH of claim 2 , wherein said basic amino acids in the α subunit are at positions 13, 14, 17, and 20.
7. The modified LH of claim 2 , said α subunit further comprising a fifth basic amino acid at a position selected from the group consisting of positions 11, 13, 14, 16, 17, and 20.
8. The modified LH of claim 7 , wherein said basic amino acids in the α subunit are at positions 13, 14, 16, 17, and 20.
9. The modified LH of claim 7 , wherein said basic amino acids in the α subunit are at positions 11, 13, 14, 16 and 20.
10. The modified LH of claim 1 , wherein said basic amino acids in the α subunit are at positions 11, 13, 14, 16, 17, and 20.
11. The modified LH of claim 1 , wherein said basic amino acids in the α subunit are at positions 13, 16, and 20.
12. The modified LH of claim 1 , wherein the basic amino acids are lysine.
13. The modified LH of claim 1 , wherein the basic amino acids are selected from the group consisting of lysine and arginine.
14. A nucleic acid encoding the modified LH of claim 1 .
15. A vector comprising the nucleic acid of claim 14 , wherein the vector is suitable for expressing the nucleic acid.
16. A host comprising the vector of claim 15 , wherein the host is suitable for expressing the nucleic acid.
17. The modified LH of claim 1 further modified so that the modified LH has less than five amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
18. The modified LH of claim 1 , wherein the modified LH has less than four amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
19. The modified glycoprotein hormone of claim 1 , wherein the modified LH has less than three amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
20. The modified LH of claim 1 , wherein the modified LH has less than two amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
21. The modified LH of claim 1 , wherein the modified LH has complete amino acid sequence homology with human LH in positions other than positions 11, 13, 14, 16, 17, and 20 of the α-subunit.
22. A modified human luteinizing hormone (LH) comprising a basic amino acid in the α-subunit in at least one position selected from the group consisting of positions 11, 13, 14, 16, 17 and 20.
23. The modified LH of claim 22 , wherein a basic amino acid is at position 11.
24. The modified LH of claim 22 , wherein a basic amino acid is at position 13.
25. The modified LH of claim 22 , wherein a basic amino acid is at position 14.
26. The modified LH of claim 22 , wherein a basic amino acid is at position 16.
27. The modified LH of claim 22 , wherein a basic amino acid is at position 17.
28. The modified LH of claim 22 , wherein a basic amino acid is at position 20.
29. The modified LH of claim 22 , wherein the basic amino acid is selected from the group consisting of lysine and arginine.
30. The modified LH of claim 22 , comprising a basic amino acid in at least two positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20.
31. The modified LH of claim 30 , wherein the basic amino acids are at positions 16 and 20.
32. The modified LH of claim 30 , wherein the basic amino acids are at positions 16 and 13.
33. The modified LH of claim 30 , wherein the basic amino acids are at positions 20 and 13.
34. The modified LH of claim 30 , wherein the basic amino acid is selected from the group consisting of lysine and arginine.
35. A nucleic acid encoding the modified LH of claim 22 .
36. A vector comprising the nucleic acid of claim 22 , wherein the vector is suitable for expressing the nucleic acid.
37. A host comprising the vector of claim 36 , wherein the host is suitable for expressing the nucleic acid.
38. The modified LH of claim 22 further modified so that the modified LH has less than five amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
39. The modified LH of claim 22 , wherein the modified-LH has less than four amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
40. The modified LH of claim 22 , wherein the modified-LH has less than three amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
41. The modified LH of claim 22 , wherein the modified LH has less than two amino acid substitutions in the α-subunit in positions other than positions 11, 13, 14, 16, 17, and 20.
42. The modified LH of claim 22 , wherein the modified LH has the complete amino acid sequence homology with the wild-type LH in positions other than positions 11, 13, 14, 16, 17, and 20 of the α-subunit.